01—Abstract
Summary
Summary of the 10-K filed February 8, 2021. Cited figures are marked; the original filing is the authoritative source.
Mettler-Toledo International Inc. reported net sales of $3.09 billiona for 2020, up from $3.01 billion in 2019 and $2.94 billion in 2018.
Net sales rose 3% in U.S. dollars and 2% in local currencies in 2020, while the filing states COVID-19 negatively affected global customer demand during the year. Net earnings increased to $602.7 millionb ($24.91 diluted EPS) from $561.1 million ($22.47 diluted EPS) in 2019. Gross margin improved to 58.4% of net sales from 57.9%, reflecting favorable price realization and temporary cost savings, and cash provided by operating activities rose to $724.7 million.
Laboratory products and services represented approximately 54%c of 2020 net sales, industrial approximately 40%, and food retailing approximately 6%. Management highlighted strong pipette growth and biopharma demand in laboratory products, while product inspection and food retailing declined. Chinese Operations grew sales to external customers 6% in U.S. dollars.
The company also noted it repurchased $775 milliond of common stock in 2020 and that the Board authorized an additional $2.5 billion in November 2020, leaving $3.1 billion of remaining availability at year-end. Balance sheet leverage is a key consideration: total debt was $1.33 billion at December 31, 2020, against cash of $94.3 million, and shareholders' equity fell to $282.7 million from $420.8 million as buybacks and other comprehensive losses exceeded earnings.
The filing also states that Olivier A. Filliol will step down as CEO on April 1, 2021, succeeded by Patrick Kaltenbach.
02—Key points
Key Highlights
- Net sales of $3.09 billion in 2020, up 3% in U.S. dollars and 2% in local currencies, with COVID-19 cited as a negative factor on customer demand.
- Net earnings of $602.7 million and diluted EPS of $24.91, compared with $561.1 million and $22.47 in 2019.
- Gross profit as a percentage of net sales rose to 58.4% from 57.9%, driven by favorable price realization and temporary cost savings.
- Laboratory products represented about 54% of net sales, industrial about 40%, and food retailing about 6%; pipettes showed very strong growth.
- Cash provided by operating activities was $724.7 million; capital expenditures were $92.5 million.
- Shareholders' equity declined to $282.7 million, while total debt was $1.33 billion against $94.3 million of cash.
- The Board authorized an additional $2.5 billion for share repurchases in November 2020, with $3.1 billion of availability remaining at December 31, 2020; CEO Olivier A. Filliol steps down April 1, 2021.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 8, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $3.09B$3.01B | +2.5% |
| Gross Profit | $1.80B$1.74B | +3.4% |
| R&D Expenses | $140.10M$143.95M | −2.7% |
| SG&A Expenses | $820.22M$819.18M | +0.1% |
| Interest Expense | $38.62M$37.41M | +3.2% |
| Net Income | $602.74M$561.11M | +7.4% |
| EPS (Basic) | $25.24$22.84 | +10.5% |
| EPS (Diluted) | $24.91$22.47 | +10.9% |
| Shares Outstanding (Basic) | 23.88M24.57M | −2.8% |
| Shares Outstanding (Diluted) | 24.20M24.97M | −3.1% |
05—Questions
Frequently Asked Questions
How did Mettler-Toledo perform financially in 2020?
Net sales were $3.09 billion, up 3% in U.S. dollars and 2% in local currencies. Net earnings were $602.7 million, or $24.91 per diluted share, up from $22.47 in 2019. Operating cash flow was $724.7 million.
What is the company's exposure to China?
The filing states Chinese operations accounted for 19% of sales to external customers, about 32% of global production, and 32% of total segment profit in 2020. It also notes $43.2 million of cash held in Chinese subsidiaries at December 31, 2020, and that repatriating funds requires government approval.
How much debt does the company carry and how much is available to borrow?
Total debt was $1.33 billion at December 31, 2020, including $791.1 million of senior notes and $491.4 million outstanding under the $1.1 billion Credit Agreement. Approximately $602.5 million of additional borrowings were available under the Credit Agreement, which matures June 15, 2023.
Does the company pay dividends and how is it returning capital?
The company has not historically paid dividends on its common stock and will evaluate that policy periodically. In 2020 it spent $775 million repurchasing 815,652 shares at an average price of $950.14, and it has $3.1 billion of remaining repurchase authorization.
Who is leading the company and what changes are planned?
Olivier A. Filliol, President and CEO since January 2008, will step down as CEO effective April 1, 2021, and remain a director. Patrick Kaltenbach, who joined in January 2021 as CEO Designate, will assume the CEO role on April 1, 2021.
06—Continue